

Connectome predictive modelling of PTSD symptom severity

Amanda Tamman, Lynnette Averill, Chris Averill, Chadi Abdallah

- No new FDA approved drugs for PTSD since 2001
- Early stages of drug discovery based on hypothesis driven region of interest approaches
- Data-driven/network-based approach: identify new targets for clinical trials

Quality of evidence	Recommend FOR	Suggest FOR
High	None	None
Moderate	Paroxetine*, sertraline*, venlafaxine *FDA approved	None
Low	None	Prazosin (only for the treatment of PTSD-associated nightmares)

- What we did:
 - Generated connectome “fingerprint” correlated with PTSD symptoms
- What we found:
 - Cross-network hypoconnectivity
 - Default mode and central executive reduced functional connectivity dominated
 - Visual network lower and higher connectivity
- Clinical implications:
 - Drugs/neuromodulation to modulate networks of interest
 - Clinical trial design: target engagement and individualized biomarker-driven treatments

